PF-06671008 Dose Escalation Study in Advanced Solid Tumors

• Status: Terminated
• Trial end date: 2019-03-29
• Target enrollment: 0
• Participant gender: All

Summary

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Key Inclusion Criteria

• Diagnosis of tumor type with the potential to have P-cadherin expression that is resistant to standard therapy or for which no standard therapy is available

• Performance status of 0 or 1

• Adequate bone marrow, kidney and liver function

Key Exclusion Criteria

• Known CNS disease including, but not limited to, metastases

• Current or history of seizure disorder

• History of or active autoimmune disorders

• Active bacterial, fungal or viral infection

• Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study treatment

• Requirement for systemic immune suppressive medication

• Grade 2 or greater peripheral neuropathy